



PATENT APPLICATION

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation Number: 2881

Christelle PRAGNON, et al.

Atty.Docket No.: 021305-00214

Serial No.: 10/539,406

Group Art Unit: 1657

Filed: November 23, 2005

Examiner: Paul C. Martin

For: METHOD FOR ANALYZING TUMOR AGGRESSIVITY COMPRISING
MEASUREMENT OF POLYMERIZED ACTIN

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Date: May 17, 2007

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☐ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☒ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☒ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge

after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

☒ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.

☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).


In the event that any fees are due with respect to this paper, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 01-2300, referencing Atty. Docket No. 021305-00214.

Respectfully submitted,

05/22/2007 MKAYPAGH 00000089 10539406


02 FC:1806

180.00 OP


Dawn C. Russell
Registration No. 44,751

Customer No. 004372
ARENT FOX LLP
1050 Connecticut Avenue, N.W.,
Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

DCR:sg



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A/PTO**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO/SB/08a**Complete if Known**

Sheet	1	of	1	Application Number	10/539,406
				Filing Date	November 23, 2005
				First Named Inventor	PRAGNON
				Art Unit	1657
				Examiner Name	Paul C. Martin
				Attorney Docket Number	021305-00214

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-				
		US-				

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Country Code ³	Number* Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		01/71356	WO	A	09-27-2001	Julie FRADELIZI et al.		
		99/11814	WO	A	03-11-1999	University Leland Stanford Junior		
		01/41815	WO	A	06-14-2001	Dana Farber Cancer Inst.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		Damiano, J. S. et al. (2001). "Cell adhesion mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation." Leukemia 15(8): 1232-9.	
		Faute, M. A. et al. (2002). "Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D cultures of NCF-7, a human breast cancer cell line, and its multidrug resistant variant." Clin Exp Metastasis 19(2): 161-8.	
		Dugray, A. et al. (2001). "Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette." Leukemia 15: 1658-62.	
		Fradelizi, J. et al. (2001). "ActA and human zyxin harbour Arp2/3-independent acting polymerization activity." Nat Cell Biol 3(8) 699-707.	
		Lopes, E. C. et al. (2001). "Dissimilar invasive and metastatic behavior of vincristine and doxorubicin-resistant cell lines derived from a murine T cell lymphoid leukemia." Clin Exp Metastasis 19(4): 283-90.	
		Machesky, L. M. et al. (1999). "Scar, a WASp-related protein, activates nucleation of actin filaments by the Arp2/3 complex." Proc Natl Acad Sci U S A 96(7): 3739-44.	
		Mitsumoto, M. et al. (1998). "Emergence of higher levels of invasive and metastatic properties in the drug-resistant cancer cell lines after the repeated administration of cisplatin in tumor-bearing mice." J Cancer Res Clin Oncol 124(11): 607-14.	
		Nakamura, K. et al. (2002). "Characterization of murine melanoma cell lines by their mortal malignancy using an experimental metastatic model." Life Sci 70(7): 791-8.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.